Matter Bio is a company that appears to specialize in the biotechnology sector, potentially focusing on the development of therapeutics, diagnostics, or biotech research services.

Matter Bio

Matter Bio is a longevity holding company focused on preserving genome integrity

As we age, our genome is constantly being damaged by exogenous and endogenous sources.

 Occasionally errors are missed and incorporated into the DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss.
 
At Matter, we have assembled a world-class team of scientists and executives to help counter this critical information loss in the genome.

To achieve this, we are focusing on a number of assets that address key stages in the genomic information loss continuum.

Age is inevitable. Aging is not.
Matter Bioworks, Christopher Bradley, and Sam Sharifi, PhD are new members at ShareLab.

Matter Bio is a US longevity holding company focused on preserving genome integrity. Matter's core assets comprise accurate mutation sequencing, improving endogenous DNA repair, removing somatic mutations, and removing overly corrupted cells altogether. The company's current co-founders include Prof George Church (Harvard Medical School), Prof Jan Vijg, Assoc Profs Alexander Maslov and claudia Gravekamp (all three at Albert Einstein College of Medicine), and other top scientists. 

Sam will be running Matter Bio's campaign in the (Share)lab. He is Dutch, a biogerontologist with a PhD from the University of Jena.

#biotech #longevity #oslo #sharelab

COM:MATTERBIO

Matter Bio

market

industry

website

crunchbase

linkedin

investor of

Metrics